Document:

Exhibit
10.31

 

CONSULTING AGREEMENT

 

This Agreement (“Agreement”)
is entered into on the 7th day of August, 2010, between Sabre Industries, Inc.
whose address is 1120 Welsh Road, Ste. 210 North Wales, PA 19454  (hereinafter “Company”) and David de Poincy whose
address is 2117 Dana Court, Flower Mound, Texas 75028 (hereinafter “Consultant”).

 

For good and valuable consideration which
sufficiency is hereby acknowledged, the parties hereto agree as follows:

 

1.             Term. The term of
this Agreement shall be for six (6) months, beginning June 7, 2010,
and shall be month-to-month following expiration of the initial six (6) month
period.  The Agreement may be terminated
by either party upon sixty (60) days’ written notice.

 

2.             Services.  Consultant agrees that he possesses specific
knowledge and experience from his prior employment at Company that may be
needed from time to time.  In the event
Company requests assistance from Consultant, Consultant agrees to cooperate and
assist Company as requested in Company’s sole discretion.  This assistance shall include, but not be
limited to, participation on conference calls, availability for telephonic and
in-person consultation, and on-site assistance with operations at any facility
or at the site of ongoing field operations for Company, upon receiving
reasonable notice of such a request.

 

3.             Compensation. Company
shall, during the Term of this Agreement, pay Consultant $16,500.00 per month
as compensation for the Services.  If Consultant is requested
to appear in person at any Company facility or in the field, Company shall
reimburse Consultant for all reasonable travel expenses.

 

4.             Independent
Contractor Relationship. The relationship of
Consultant and/or his employees (hereinafter Consultant) to Company is solely
that of an independent contractor. Consultant is solely responsible for the
conduct and control of the Services and is not an employee of Company for any
purpose. Consultant is solely responsible for and shall pay all federal, state
and local income taxes, Social Security taxes and any other similar
obligations, under any law or regulation, domestic or foreign, arising from its
performance of this Agreement or receipt of compensation thereof. Consultant
understands that no medical, dental, health, vacation or sick leave or other
benefits including, without limitation, stock option or bonus plans, and/or 401(K) contributions
and/or participation, provided to Company’s employees shall be provided to
Consultant by Company during or after the term of this Agreement. Consultant
shall promptly return all equipment purchased by Company for Consultant’s use
during the term of this Agreement to Company at the termination of this
Agreement. Consultant shall not enter into, nor represent it has the authority
to enter into, any contracts or commitments on behalf of Company, and shall
hold Company harmless from any loss, damage, liability or expense resulting
from any illegal or tortuous acts or omissions of Consultant.

 

5.             Consultant Warrants.

 

a.             Consultant
and/or his employees (hereinafter Consultant) has the experience and skills
necessary to perform and provide the Services required pursuant to this
Agreement. All Services provided by Consultant shall be performed (a) in a
professional manner, with a high grade, nature and quality, commensurate with
that which is customary in the industry, and (b) in compliance with all
applicable federal, state and local laws, rules, regulations and ordinances and
of Company’s applicable rules while Consultant is on Company’s premises.

 

b.             Consultant
shall not, without Company’s prior written approval, alter, enlarge or limit
orders, make representations or guarantees concerning Company’s Authorized
Products and Services or accept the return of, or make allowance for such
Authorized Products and Services.

 

c.             Consultant
shall furnish to Company’s Credit Department any information, which 

 

1

 

Consultant
may have from time to time relative to the credit standing of any of Consultant’s
customers.

 

d.             Consultant
shall abide by Company’s policies and communicate the same to Company’s
customers when applicable.

 

e.             Consultant
shall not directly or indirectly call upon or solicit any customer with the
intention of diverting or attempting to divert such customer to use any
equivalent to products and services of the Company.

 

6.             Confidential
Information.

 

a.             Company Information.  Consultant agrees at all times during the
term of this Agreement, to hold in strictest confidence, and not to use, except
for the benefit of Company, or to disclose to any person, firm, corporation or
other entity without written authorization of Company, any Confidential
Information of Company which Consultant obtains or creates.  Consultant further agrees not to make copies
of such Confidential Information except as authorized by Company.

 

Consultant
understands that “Confidential Information” means any Company proprietary
information, technical data, trade secrets, or know-how, including, but not
limited to, information relating to past, present, or future business of
Company, or any plans therefore, market information, actual or prospective
personnel or clients, strategy, budgets, pricing, research, development,
operating results, services, business plans or designs, cost and pricing strategies
or information, client requirements and preferences, marketing research, work
product (including all documentation, creative works, know-how and information
created in whole or in part by Consultant during Consultant’s Relationship with
Company whether or not copyrightable or otherwise protectable) or other
competitively sensitive business information, and all related databases,
compilations and records disclosed to Consultant by Company, either directly or
indirectly, in writing, orally or by drawings or observation by Consultant
during the period of the Relationship, whether or not during working hours.

 

Consultant
understands that “Confidential Information” includes, but is not limited to,
information pertaining to any aspects of Company’s business which is either
information not known by actual or potential competitors of Company or is
proprietary information of Company or its customers or suppliers, whether of a
technical nature or otherwise. Consultant further understands that “Confidential
Information” does not include any of the foregoing items which have become
publicly and widely known and made generally available (without expending
significant time or effort) through no wrongful act of Consultant’s or of
others who were under confidentiality obligations as to the item or items
involved.

 

All
“Confidential Information” is and shall remain Company’s exclusive property,
and Consultant further agrees that all information used by Consultant in
connection with his/her job is confidential and valuable property of Company,
and that any such information developed by Consultant during the performance of
such employment is and shall remain the exclusive property of Company.  Consultant recognizes and acknowledges that
Company’s business matters and affairs (including, but not limited to, the
nature and extent of Company’s assets and holdings and any information related
to Company’s business relationships, developmental concepts, business practices
and policies, pricing structures, methods of business operation, operational
techniques, banking and lending relationships, or details of any financial
information related to the size and scope of Company,) are valuable to Company
and included within the definition of Confidential Information.

 

b.             Former Contractor or
Employee Relationship. Consultant represents that performance of
all terms of this Agreement as a Consultant has not breached and will not
breach any agreement to keep in confidence proprietary information, knowledge
or data acquired by Consultant in confidence or trust prior or subsequent to
the commencement of this Agreement and/or the payment of commissions to
Consultant by Company, and Consultant will not disclose to Company direct or
advise Company to use, any inventions, confidential or proprietary information
or material belonging to any previous employer or any other party.

 

2

 

7.             Non-Compete.  Independent of any
obligation under any other contract or agreement between Consultant and
Company, and in consideration for the amounts paid pursuant to Paragraph 3,
during the performance of this Agreement in the continental United States and
any geographic region outside the continental United States in which Company
does business, Consultant shall not, directly or indirectly, whether as an
individual for his own account or for the benefit of others, own, manage,
operate, join, control, finance or participate in, or participate in the
ownership, management, operation, control or financing of, or be connected as a
principal, agent, representative, consultant, employee, investor, owner,
partner, manager, joint venturer or otherwise with, or permit his name to be
used by or in connection with any business, enterprise or other entity engaged
in competition with Company or its parent or subsidiary corporations or any
other entities affiliated with Company (its “Affiliates”) in any area in which
Company or its Affiliates does business (provided, however, that the
restrictions set forth in this clause shall not apply to involvement that
consists solely of “beneficially owning,” as such term is used in Rule 13d-3
promulgated under the Exchange Act, 2% or less of the outstanding securities of
any class of securities issued by a publicly-traded entity).

 

8.             Non-Solicitation.  In consideration for a
portion of the compensation paid pursuant to Paragraph 3, Consultant shall not,
directly or indirectly:

 

a.             For the duration of this
Agreement, contact with intent to solicit, hire, or attempt to contact, solicit
or hire any employee or independent contractor personnel of Company or its
Affiliates with whom Consultant had personal contact and did business with
while employed by Company;

 

b.             For the duration of this
Agreement, solicit, call upon or otherwise contact or offer products or
services to any customers or accounts of Company or its Affiliates with which
Consultant had any contact or association;

 

c.             For the duration of this
Agreement,  solicit or attempt to induce
or cause any employee of Company or its Affiliates to leave the employ of
Company or its Affiliates; or hire or otherwise accept the services of any
employee or former employee of Company or its Affiliates, whether solicited or
not solicited by Consultant;

 

d.             For the duration of this
Agreement, induce or attempt to induce any supplier, licensee or other business
relation of the Company or its Affiliates to cease doing business with the
Company or its Affiliates, or in any way interfere with the relationship
between any such supplier, licensee or business relation and Company (or its
Affiliates).

 

9.             Injunctive
Relief.  The parties
acknowledge that Consultant’s breach of any provision of this Agreement will
cause Company irreparable injury and damage. 
Consultant, therefore, expressly agrees that Company shall be entitled
to injunctive and other equitable relief in the event of, or to prevent, his
breach of any provision of this Agreement. 
Exercise of rights to equitable relief, however, shall not be construed
as waiver of any other right or remedy the Company may have for damages or
otherwise.

 

10.          Return
of Company Documents. 
Consultant agrees that, at the time of termination of this Agreement, it
will deliver to Company (and will not keep in his/her possession, recreate or
deliver to anyone else) any and all devices, records, data, notes, reports,
proposals, lists, correspondence, specifications, drawings, blueprints,
sketches, laboratory notebooks, materials, flow charts; equipment, other
documents or property, or reproductions of any aforementioned items developed
by Consultant pursuant to the terms of this Agreement or otherwise belonging to
Company, its successors or assigns. 
Consultant further agrees that any property situated on Company’s
premises and owned by Company, including disks and other storage media, filing
cabinets or other work areas, is subject to inspection by Company personnel at
any time with or without notice.

 

3

 

11.          Representations
and Covenants.

 

a.             Consultant agrees to execute
promptly any proper oath, or verify any proper document, required to carry out
the terms of this Agreement upon Company’s reasonable and necessary written
request to do so.

 

b.             Consultant hereby warrants
that he/she is not now under any legal or contractual obligation that would
conflict in any manner with the obligations and duties he/she is undertaking
herein, and that his/her execution of this Agreement will not breach any
agreement to which he/she is now a party.

 

c.             Consultant certifies and
acknowledges that he/she has carefully read all of the provisions of this
Agreement and that he/she understands and will fully comply with such
provisions.

 

12.          General
Provisions.

 

a.             In the event
any of the foregoing restrictions are held to be in any respect an unreasonable
restriction upon Consultant, then the court so holding shall reduce the
territory to which it pertains and/or the period of time in which it operates,
or effect any other change to the extent necessary, to render any of the
restrictions enforceable.  Each of the
terms and provisions of this Agreement is, and is to be deemed, severable in
whole or in part, and if any term or provision, or the application thereof to
circumstances other than those as to which it is held invalid, illegal or
unenforceable, shall not be affected thereby, and shall remain in full force
and effect.

 

b.             The captions
contained herein are solely for the convenience of the parties, and shall not
be deemed to govern the meaning or intent of any of the provisions of this
Agreement.

 

c.             The rights and
obligations of Company hereunder shall inure to the benefit of, and be binding
upon, any successor or assign of Company. 
This Agreement is personal to Consultant and Consultant may not assign
his rights or delegate his shall not be assigned by it to any other party
whatsoever.

 

d.             The waiver or
non-enforcement by Company, of any breach of any provision of this Agreement,
shall not operate or be construed as a waiver of any subsequent breach by
Consultant.

 

e.             This Agreement,
unless stated otherwise herein, may only be amended by the written mutual
agreement of the parties hereto.

 

f.              The provisions
of this Agreement shall survive the assignment of this Agreement by Company to
any successor in interest or other assignee.

 

g.             Consultant
acknowledges and specifies that this Agreement is supported by adequate
consideration in the form of Consultant’s contract for services with Company.

 

h.             Consultant
acknowledges and specifies that he entered knowingly into this Agreement.

 

13.          Non-Disparagement.  The parties agree that their professional and
personal reputations are important and should not be impaired by either party
after this Agreement is executed. 
Consultant agrees not to disparage the professional or personal
reputation of Company, its officers, shareholders, directors, or management,
and Company agrees that it will not disparage Consultant’s professional or
personal reputation.

 

14.          Indemnity.  Excluding any claims based upon the
negligence, willful misconduct, or breach of this Agreement by Company,
Consultant hereby agrees to indemnify, defend and hold Company harmless from
and against any and all claims, damages, losses and expenses, including but not
limited to attorneys’ fees and disbursements, arising out of or resulting from
any claim, action or other proceeding (including without limitation any
proceeding by any of that is based upon (a) Consultant’s breach of this
Agreement, (b) the unauthorized conduct or actions of Consultant within or
outside the scope of this Agreement, or (c) any negligent act or omission
or willful misconduct of Consultant.

 

4

 

15.          Governing
Law. This Agreement and the obligations of the parties
hereunder shall be interpreted, construed and enforced in accordance with the
laws of Texas, except for its conflict of laws rules and principles. Any
legal action or proceedings with respect to this Agreement shall be initiated
in the jurisdiction of the state or federal courts of the State of Texas and
venued in the State of Texas for resolution.

 

16.          Disputes
and Arbitration.  The parties
agree that any disputes or questions arising during the performance of this
Agreement, including any disputes regarding the construction or application of
this Agreement, shall be arbitrated in accordance with the rules of the
American Arbitration Association then in force. 
If the parties cannot agree on an arbitrator within ten (10) days
after a demand for arbitration is made by either party, either or both parties
may request the American Arbitration Association to name a panel of five (5) arbitrators.  Company shall then strike two (2) names
on the list and Consultant shall then strike two (2) names from the list
and the remaining name shall be the arbitrator. 
The decision of the arbitrator shall be final and binding upon the
parties both as to law and to fact, and shall not be appealable to any court in
any jurisdiction over the parties.  The
expenses of the arbitrator shall be shared equally by the parties, unless the
arbitrator determines that the expenses shall be otherwise assessed.

 

17.          Termination. Either party may terminate
this Agreement for any reason, or for no reason, by written notice of
termination via certified mail, return receipt requested, at the address in
Paragraph 18 of this Agreement.  Such
termination shall be effective sixty (60) days after the date of postmark of
any notice.  The ability of either party
to terminate this Agreement shall in no way be interpreted as an at-will
employment provision and shall not otherwise affect Consultant’s status as an
independent contractor under this Agreement. 
In the event of a termination, compensation due pursuant to Paragraph 3
for the month in which the Agreement was terminated shall be prorated to the
date of termination, with no further compensation due after the date of
termination.  In the event Company
terminates the Agreement for a breach by Consultant, Consultant shall not be
entitled to further payments of the base compensation or payment of commissions
set forth in Paragraph 3 earned beyond the date of the breach.

 

18.          Notices.  Any notice or other communication required or
desired to be given in this Agreement shall be in writing and addressed to the
parties, respectively, as follows:

 

David
de Poincy

2117
Dana Court

Flower
Mound, Texas  75028

(817)
948-5733

 

James
D. Mack

Sabre
Industries, Inc.

1120 Welsh Road, Suite 210

Gwynedd Corporate Center

North Wales, PA 19454

 

19.          Entire
Agreement; Modifications. This Agreement
constitutes the entire agreement and understandings between the parties, and
supersedes all offers, negotiations and other agreements concerning the subject
matter contained herein. This Agreement, however, shall not supersede or
replace the terms of the Severance Agreement and Release between de Poincy and
Sabre.  This Agreement may not be
modified in any way without the written consent of both parties.

 

IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first above written.

 

5

 

	
  David
  de Poincy

  	
   

  	
  Sabre
  Industries, Inc.,

  
	
   

  	
   

  	
  a
  Delaware Corporation

  
	
   

  	
   

  	
   

  
	
  By:

  	
  /s/
  David J. de Poincy

  	
   

  	
  By:

  	
  /s/
  James M. Tholey

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Date:

  	
  8/7/10

  	
   

  	
  Name:

  	
  J.M.
  Tholey

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  Date:

  	
  8/9/10

  

 

6Exhibit 4.3  

        ANACOR PHARMACEUTICALS, INC.
A DELAWARE CORPORATION

AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

December 24, 2008  

 

  TABLE OF CONTENTS  

 

 

									
	 
	 	 
	 	 
	 	Page 	 
	 1.
	 	Definitions; Registration Rights	 	 	1	 
	 
	 	1.1	 	 Definitions
	 	 	1	 
	 
	 	1.2	 	 Request for Registration
	 	 	3	 
	 
	 	1.3	 	 Company Registration
	 	 	4	 
	 
	 	1.4	 	 Form S-3 Registration
	 	 	5	 
	 
	 	1.5	 	 Obligations of the Company
	 	 	6	 
	 
	 	1.6	 	 Furnish Information
	 	 	7	 
	 
	 	1.7	 	 Expenses of Registration
	 	 	7	 
	 
	 	1.8	 	 Delay of Registration
	 	 	8	 
	 
	 	1.9	 	 Indemnification
	 	 	8	 
	 
	 	1.10	 	 Reports Under Securities Exchange Act of 1934
	 	 	10	 
	 
	 	1.11	 	 Assignment of Registration Rights
	 	 	11	 
	 
	 	1.12	 	 Limitations on Subsequent Registration Rights
	 	 	11	 
	 
	 	1.13	 	 Market-Standoff Agreement
	 	 	11	 
	 
	 	1.14	 	 Termination of Registration Rights
	 	 	12	 
	 2.
	 	Covenants of the Company	 	 	12	 
	 
	 	2.1	 	 Delivery of Financial Statements
	 	 	12	 
	 
	 	2.2	 	 Budget Approval
	 	 	13	 
	 
	 	2.3	 	 Inspection
	 	 	13	 
	 
	 	2.4	 	 Books and Records
	 	 	13	 
	 
	 	2.5	 	 Board Expenses
	 	 	13	 
	 
	 	2.6	 	 Right of First Offer
	 	 	13	 
	 
	 	2.7	 	 Employee Agreements
	 	 	15	 
	 
	 	2.8	 	 Termination of Covenants
	 	 	15	 
	 3.
	 	Miscellaneous	 	 	15	 
	 
	 	3.1	 	 Entire Agreement
	 	 	15	 
	 
	 	3.2	 	 Recapitalizations, Etc. 
	 	 	15	 
	 
	 	3.3	 	 Successors and Assigns
	 	 	15	 
	 
	 	3.4	 	 Amendments and Waivers
	 	 	15	 
	 
	 	3.5	 	 Notices
	 	 	16	 
	 
	 	3.6	 	 Severability
	 	 	16	 
	 
	 	3.7	 	 Delays or Omissions; Remedies Cumulative
	 	 	16	 
	 
	 	3.8	 	 Attorneys' Fees
	 	 	16	 
	 
	 	3.9	 	 Governing Law
	 	 	16	 
	 
	 	3.10	 	 Counterparts
	 	 	16	 
	 
	 	3.11	 	 Titles and Subtitles
	 	 	16	 
	 
	 	3.12	 	 Aggregation of Stock
	 	 	16	 
	 
	 	3.13	 	 Confidentiality
	 	 	17	 
	 
	 	3.14	 	 Additional Parties
	 	 	17	 
	 
	 	3.15	 	 Strategic Investors Other Rights
	 	 	17	 

 

 i

 ANACOR PHARMACEUTICALS, INC.

A DELAWARE CORPORATION

 AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT  

        This Amended and Restated Investors' Rights Agreement (this "Agreement") is made as of
December 24, 2008, by and among Anacor Pharmaceuticals, Inc., a Delaware corporation (the "Company"), the investors listed on  Exhibit A
hereto (each, an "Investor"), The Pennsylvania State University and Stanford
University. 

 RECITALS  

        The Company, certain of the Investors, The Pennsylvania State University and Stanford University have previously entered into an
Amended and Restated Investors' Rights Agreement dated as of June 13, 2006 (the "Prior Rights Agreement"). The Company and certain of the
Investors have entered into a Series E Preferred Stock Purchase Agreement (the "Purchase Agreement") of even date herewith pursuant to which the
Company is selling to such Investors and such Investors are purchasing from the Company shares of the Company's Series E Preferred Stock. A condition to the parties' obligations under the
Purchase Agreement is that the Company and the Investors enter into this Agreement in order to provide the Investors with (i) certain rights to register shares of the Company's Common Stock
issuable upon conversion of the Series E Preferred Stock held by the Investors, (ii) certain rights to receive or inspect information pertaining to the Company, and (iii) a right
of first offer with respect to certain issuances by the Company of its securities as set forth herein. The Company desires to induce the Investors to purchase shares of Series E Preferred Stock
pursuant to the Purchase Agreement by agreeing to the terms and conditions set forth herein. 

 AGREEMENT  

        The parties hereto agree as follows: 

        A.    Amendment of Prior Rights Agreement; Waiver of Right of First Offer.    Effective and
contingent upon execution of this Agreement by the Company and the holders of at least 60% of the Registrable Securities, as that term is defined in the Prior Rights Agreement, and upon closing of the
transactions contemplated by the Purchase Agreement, the Prior Rights Agreement is hereby amended and restated in its entirety to read as set forth in this Agreement, and the Company and the holders
of the Registrable Securities hereby agree to be bound by the provisions hereof as the sole agreement of the Company and the holders of the Registrable Securities with respect to registration rights
of the Company's securities and certain other rights, as set forth herein. The holders of Registrable Securities, as that term is defined in the Prior Rights Agreement, on behalf of themselves and all
holders of Registrable Securities pursuant to Section 3.4 of the Prior Rights Agreement, hereby waive any right of first offer, including the notice requirements related thereto, set forth in
Section 2.7 of the Prior Rights Agreement with respect to the issuance of Series E Preferred Stock pursuant to the Purchase Agreement. 

        1.    Definitions; Registration Rights.    

        1.1    Definitions.    

        For
purposes of this Agreement: 

        (a)   "Board" means the Board of Directors of the Company, as the same shall be constituted from time to time. 

        (b)   "Common Stock" means the common stock, par value $0.001 per share, of the Company. 

        (c)   "Exempt Registration" means a registration statement relating to the sale of securities by the Company pursuant to a
stock option, stock purchase or similar benefit plan or an SEC Rule 145 transaction. 

 

        (d)   "Form S-3" means such form under the Securities Act as in effect on the date hereof or any successor
form under the Securities Act that is intended to be used as a short form for the registration of distribution of secondary shares. 

        (e)   "Holder" means any person owning or having the right to acquire Registrable Securities or any assignee thereof in
accordance with Section 1.11 of this Agreement. 

        (f)    "Investor Holder" means any Investor and any person owning or having the right to acquire Registrable Securities
originally issued to any Investor or any assignee thereof in accordance with Section 1.11 of this Agreement. 

        (g)   "Major Investor" means any Holder of at least 800,000 Registrable Securities (as appropriately adjusted for stock splits
and the like). 

        (h)   "Person" means any individual, corporation, partnership, limited liability company, trust, business, association or
government or political subdivision thereof, governmental agency or other entity. 

        (i)    "Preferred Stock" means the Series A-1 Preferred Stock, the Series A-2 Preferred
Stock, the Series B Preferred Stock, the Series C Preferred Stock, the Series D Preferred Stock and the Series E Preferred Stock of the Company. 

        (j)    "Qualified IPO" means the firm commitment underwritten public offering by the Company of shares of its Common Stock
pursuant to a registration statement on Form S-1 (or any successor form) under the Securities Act, which results in aggregate cash proceeds to the Company of $35,000,000 (net of
underwriting discounts and commissions) at a price per share to the public of at least $3.3872 (appropriately adjusted for any stock split, dividend, combination or other recapitalization). 

        (k)   The
terms "register," "registered," and
"registration" refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Securities
Act and the declaration or ordering of effectiveness of such registration statement or document. 

        (l)    The
term "Registrable Securities" means (i) the shares of Common Stock issuable or issued upon conversion of the
Preferred Stock, provided that shares of Common Stock issued or issuable upon conversion of Series D Preferred Stock issued upon exercise of
warrants held by Lighthouse Capital Partners V, LP or its affiliates shall not be Registrable Securities for the purposes of Section 2 hereunder, and (ii) any other shares of
Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in
exchange for or in replacement of, the shares listed in clause (i) and this clause (ii); provided,  however, that the foregoing definition shall
exclude in all cases any Registrable Securities sold by a Holder in a transaction in which its rights under
this Agreement are not assigned. Notwithstanding the foregoing, securities shall only be treated as Registrable Securities if and so long as they have not been (A) sold to or through a broker
or dealer or underwriter in a public distribution or a public securities transaction, or (B) sold in a transaction exempt from the registration and prospectus delivery requirements of the
Securities Act under Section 4(1) thereof so that all transfer restrictions, and restrictive legends with respect thereto, if any, are removed upon the consummation of such sale. 

        (m)  The
number of shares of "Registrable Securities then outstanding" shall equal the number of shares of Common Stock
outstanding which are, and the number of shares of Common Stock issuable pursuant to then exercisable or convertible securities which are, Registrable Securities. 

2

 

        (n)   "SEC" means the Securities and Exchange Commission or any other federal agency at the time administering the Securities
Act. 

        (o)   "Securities Act" means the Securities Act of 1933, as amended. 

        (p)   "Series A Preferred Stock" means the Series A-1 Preferred Stock and
Series A-2 Preferred Stock of the Company. 

        (q)   "Strategic Investor" means any Investor that is designated a "Strategic Investor" on a signature page hereto. 

        1.2    Request for Registration.    

        (a)    Initiation.    If the Company shall receive at any time after the earlier of
(i) December 31, 2011, or (ii) six months after the effective date of the first registration statement of the Company pertaining to its Common Stock (other than an Exempt
Registration), a written request from the Investor Holders of at least a majority of the Registrable Securities then outstanding (the "Initiating
Holders") that the Company file a registration statement under the Securities Act, and if the aggregate offering price to the public (net of any underwriters' discounts
or commissions) shall be reasonably expected by the Company to be at least $5,000,000, then the Company shall, within 10 days of the receipt thereof, give written notice of such request to all
other Holders and shall, subject to the limitations of subsections 1.2(b), (c), (d) and (e), use its reasonable best efforts to effect as soon as practicable the registration under the
Securities Act of all Registrable Securities which the Initiating Holders request to be registered, together with any Registrable Securities of any Holder joining in such request as are specified in a
written notice given by any such Holder to the Company within 20 days after receipt of the Company's notice. 

        (b)    Underwritten Offering.    If the Initiating Holders intend to distribute the
Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 1.2 and the Company shall
include such information in the written notice referred to in Section 1.2(a). The underwriter shall be selected by a majority in interest of the Initiating Holders and shall be reasonably
acceptable to the Company. The right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder's participation in such underwriting. All Holders
proposing to distribute Registrable Securities through such underwriting shall (together with the Company as provided in Section 1.5(e)) enter into an underwriting agreement in customary form
with the underwriter or underwriters selected for such underwriting. Notwithstanding any other provision of this Section 1.2, if the underwriter advises the Initiating Holders in writing that
marketing factors require a limitation of the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities which would otherwise be
underwritten pursuant hereto, and the number of shares of Registrable Securities that may be included in the underwriting shall be allocated among all participating Holders, including the Initiating
Holders, in proportion (rounded to the nearest 100 shares) to the amount of Registrable Securities of the Company then owned by each Holder; provided,  however, that the number of shares of Registrable Securities to be included in such underwriting shall not be reduced unless all other securities are
first entirely excluded from the underwriting. For purposes of the preceding apportionment, for any participating Holder that is a partnership, limited liability company or corporation, the partners,
retired partners, members, retired members and stockholders of such Holder, or the estates and family members of any such partners, members, retired partners or retired members and any trusts for the
benefit of any of the foregoing persons shall be deemed to be a single "selling stockholder," and any pro-rata reduction with respect to
such "selling stockholder" shall be based upon the aggregate number of shares carrying 

3

 

registration
rights owned by all Persons included in such "selling stockholder," as defined in this sentence. 

        (c)    Company Deferral.    If the Company shall furnish to the Initiating Holders a
certificate signed by the Chief Executive Officer of the Company stating that in the good faith judgment of the Board, it would be seriously detrimental to the Company and its stockholders for such
registration statement to be filed and it is therefore essential to defer the filing of such registration statement, the Company shall have the right to defer such filing for a period of not more than
120 days after receipt of the request of the Initiating Holders; provided, however, that the
Company may not utilize this right more than once in any 12-month period. 

        (d)    Maximum Number of Registrations.    The Company shall not be obligated to effect, or to
take any action to effect, any registration pursuant to this Section 1.2 after the Company has effected two registrations pursuant to this Section 1.2 and such registrations have been
declared or ordered effective and the securities offered pursuant to such registrations have been sold. 

        (e)    Lockout Period.    The Company shall not be obligated to effect, or to take any action
to effect, any registration pursuant to this Section 1.2 during the period starting with the date 60 days prior to the Company's good faith estimate of the date of filing of, and ending
on a date 180 days after the effective date of, a registration subject to Section 1.3 hereof; provided that if said registration statement
is not yet effective, the Company shall be actively employing in good faith its reasonable best efforts to cause such registration statement to become effective. 

        1.3    Company Registration.    

        (a)    Initiation.    If (but without any obligation to do so) the Company proposes to
register (including for this purpose a registration effected by the Company for stockholders other than the Holders) any of its stock in connection with the public offering of such securities solely
for cash (other than an Exempt Registration), the Company shall, at such time, promptly give each Holder written notice of such registration. Upon the written request of each Holder given within
20 days after receipt by such Holder of the Company's notice, the Company shall, subject to the provisions of Sections 1.3(b) and (c) below, use its reasonable best efforts to
cause to be registered all of the Registrable Securities that each such Holder has requested to be registered. 

        (b)    Underwritten Offering.    In connection with any offering involving an underwriting of
shares of the Company's capital stock, the Company shall not be required under Section 1.3(a) to include any securities of any Holder in such underwriting unless such Holder accepts the terms
of the underwriting as agreed upon between the Company and the underwriters selected by it (or by other persons entitled to select the underwriters), and then only in such quantity as the underwriters
determine in their sole discretion will not jeopardize the success of the offering by the Company. If the total amount of securities, including Registrable Securities, requested by stockholders to be
included in such offering exceeds the amount of securities to be sold other than by the Company that the underwriters determine in their sole discretion is compatible with the success of the offering,
then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters determine in their sole discretion will not
jeopardize the success of the offering (the securities so included to be apportioned pro rata (to the nearest 100 shares) among the selling stockholders
according to the total amount of securities entitled to be included therein owned by each selling stockholder or in such other proportions as shall mutually be agreed to by such selling stockholders)
but in no event shall the amount of securities of the selling Holders included in the offering be reduced below twenty-five percent 

4

 

(25%)
of the total amount of securities included in such offering, unless such offering is the initial public offering of the Company's securities, in which case, the selling stockholders may be
altogether excluded if the underwriters make the determination described above and no other stockholder's securities are included. For purposes of the preceding apportionment, for any participating
Holder that is a partnership, limited liability company or corporation, the partners, retired partners, members, retired members and stockholders of such Holder, or the estates and family members of
any such partners, members, retired partners or members and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single "selling stockholder," and any
pro-rata reduction with respect to such "selling stockholder" shall be based upon the aggregate amount of shares carrying registration rights owned by all Persons included in such "selling
stockholder," as defined in this sentence. 

        (c)    Right to Terminate Registration.    The Company shall have the right to terminate or
withdraw any registration initiated by it under this Section 1.3 prior to the effectiveness of such registration whether or not any Holder has elected to include Registrable Securities in such
registration. 

        1.4    Form S-3 Registration.    

        (a)    Initiation.    If the Company shall receive from any Holder or Holders a written
request that the Company effect a registration on Form S-3 with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company will promptly
give written notice of the proposed registration to all other Holders and as soon as practicable, subject to the provisions of Section 1.4(b) below, use its reasonable best efforts to effect
such registration of such Holder's or Holders' Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder or Holders
joining in such request as are specified in a written request given within 20 days after receipt of such notice from the Company. 

        (b)    Limitations.    Notwithstanding Section 1.4(a) above, the Company shall not be
obligated to effect any such registration pursuant to this Section 1.4 (i) if Form S-3 is not available for such offering by the Holders; (ii) if the Holders,
together with the holders of any other securities of the Company entitled for inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate
price to the public (net of any underwriters' discounts or commissions) of less than $1,000,000; (iii) if the Company shall furnish to the Holders a certificate signed by the Chief Executive
Officer of the Company stating that in the good faith judgment of the Board, it would be seriously detrimental to the Company and its stockholders for such Form S-3 registration to
be effected at such time, in which event the Company shall have the right to defer the filing of the Form S-3 for a period of not more than 120 days after receipt of the
request of the Holder or Holders under this Section 1.4; provided, however, that the Company
shall not utilize this right more than once in any 12-month period; (iv) if the Company has, within the 12-month period preceding the date of such request, already
effected two registrations on Form S-3 for the Holders pursuant to this Section 1.4; or (v) during the period ending 180 days after the effective date of a
registration statement subject to Section 1.3. Except as otherwise set forth in this Section 1.4, the Holders shall be entitled to request an unlimited number of registrations on
Form S-3. 

        (c)    S-3 Registration Not Demand Registration.    Registrations effected
pursuant to this Section 1.4 shall not be considered or counted as demands for registration or registrations effected pursuant to Section 1.2. 

        (d)    Underwritten Offerings.    The substantive provisions of Section 1.2(b) shall
apply to the registration if it relates to an underwritten offering. 

5

 

        1.5    Obligations of the Company.    Whenever required under this Section 1 to effect
the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

        (a)   Prepare
and file with the SEC a registration statement with respect to such Registrable Securities and use its reasonable best efforts to cause such registration
statement to become effective, and, in the instances of a registration initiated pursuant to Section 1.2 or 1.4 keep such registration statement effective for up to one hundred twenty
(120) days. 

        (b)   Prepare
and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as
may be necessary to comply with the provisions of the Securities Act. 

        (c)   Furnish
to the Holders such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Securities Act, and such
other documents as they may reasonably request in order to facilitate the disposition of such Registrable Securities. 

        (d)   Use
its reasonable best efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such
jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition
thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions. 

        (e)   In
the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement with the managing underwriter of such offering
in usual and customary form and consistent with the other provisions of this Agreement. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an
agreement. 

        (f)    Notify
each Holder of Registrable Securities covered by the registration statement at any time when the Company becomes aware of the happening of any event as a result
of which the registration statement or the prospectus included in such registration statement or any supplement to the prospectus (as then in effect) contains any untrue statement of a material fact
or omits to state a material fact necessary to make the statements therein (in the case of the prospectus, in light of the circumstances under which they were made) not misleading or, if for any other
reason it shall be necessary during such time period to amend or supplement the registration statement or the prospectus in order to comply with the Securities Act, whereupon, in either case, each
Holder shall immediately cease to use such registration statement or prospectus for any purpose and, as promptly as practicable thereafter, the Company shall prepare and file with the SEC, and furnish
without charge to the appropriate Holders and managing underwriters, if any, a supplement or amendment to such registration statement or prospectus which will correct such statement or omission or
effect such compliance and such copies thereof as the Holders and any underwriters may reasonably request. In any such event, the number of days for which such registration statement is required to be
effective hereunder shall be extended accordingly. 

        (g)   Cause
all such Registrable Securities registered pursuant hereunder to be listed on each securities exchange or over-the-counter market on which
similar securities issued by the Company are then listed, if applicable. 

6

 

 

        (h)   Provide
a transfer agent and registrar for such Registrable Securities and a CUSIP number for all such Registrable Securities, in each case not later than the effective
date of such registration. 

        (i)    Use
its reasonable best efforts to furnish, at the request of any Holder requesting registration of Registrable Securities pursuant to this Section 1, on the date
that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 1, if such securities are being sold through underwriters,
or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective, (i) an opinion, dated such date,
of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the
underwriters, if any, and to the Holders requesting registration of Registrable Securities and (ii) a letter dated such date, from the independent certified public accountants of the Company,
in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders
requesting registration of Registrable Securities (to the extent the then applicable standards of professional conduct permit said letter to be addressed to the Holders). 

        (j)    Notify
each Holder of Registrable Securities covered by the registration statement of (i) the expected effective date of the registration statement and
(ii) the effectiveness on the actual effective date thereof. 

        1.6    Furnish Information.    It shall be a condition precedent to the obligations of the
Company to take any action pursuant to this Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding
itself, the Registrable Securities held by it, and the intended method of disposition of such securities as shall be required to effect the registration of such Holder's Registrable Securities. The
Company shall have no obligation with respect to any registration requested pursuant to Section 1.2 or Section 1.4 of this Agreement if, as a result of the application of the preceding
sentence, the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the number of shares or the
anticipated aggregate offering price required to originally trigger the
Company's obligation to initiate such registration as specified in subsection 1.2(a) or subsection 1.4(b), as applicable. 

        1.7    Expenses of Registration.    

        (a)    Demand and S-3 Registration.    All expenses other
than underwriting discounts and commissions incurred in connection with registrations initiated pursuant to Section 1.2 and 1.4, including all registration, filing and qualification fees,
printers' and accounting fees, fees and disbursements of counsel for the Company, and the reasonable fees up to a maximum of $30,000 and disbursements of one counsel for the selling Holders selected
by Holders selling a majority of the subject Registrable Securities with the approval of the Company, which approval shall not be unreasonably withheld, shall be borne by the Company;  provided,
however, that the Company shall not be required to pay for any expenses of any registration
proceeding begun pursuant to Section 1.2 or 1.4 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered
(in which case all participating Holders shall bear such expenses on a pro rata basis), unless the Holders of a majority of the Registrable Securities
agree to forfeit their right to one demand registration pursuant to Section 1.2; provided further,  however, that if at the time of such withdrawal,
the Holders have learned of a material adverse change in the condition, business, or prospects of the
Company from that known to the Holders at the time 

7

 

of
their request and have withdrawn the request with reasonable promptness following disclosure by the Company of such material adverse change, then the Holders shall not be required to pay any of
such expenses and shall retain their rights pursuant to Section 1.2 and 1.4, as applicable. 

        (b)    Company Registration.    All expenses other than underwriting
discounts and commissions incurred in connection with registrations of Registrable Securities initiated pursuant to Section 1.3, including (without limitation) all registration, filing, and
qualification fees, printers' and accounting fees, fees and disbursements of counsel for the Company and the reasonable fees up to a maximum of $30,000 and disbursements of one counsel for the selling
Holder or Holders selected by Holders selling a majority of the subject Registrable Securities with the approval of the Company, which approval shall not be unreasonably withheld, shall be borne by
the Company. 

        1.8    Delay of Registration.    No Holder shall have any right to obtain or seek an
injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1. 

        1.9    Indemnification.    In the event any Registrable Securities are included in a
registration statement under this Section 1: 

        (a)    Indemnification by the Company.    To the extent permitted by law, the Company will
indemnify and hold harmless each Holder, any or each agent, officer, director, stockholder or partner of each Holder, any or each grantor or beneficiary of a Holder that is a trust, any underwriter
(as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of Section 15 of the Securities Act or the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), against any losses, claims, damages, or liabilities (joint or several) to which they may become
subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon
any of the following statements, omissions or violations (collectively a "Violation"): (i) any untrue statement or alleged untrue statement of a
material fact contained in such registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or
alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the
Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law; and the Company
will pay to each such Holder, underwriter or controlling person, as incurred, any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss,
claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this
subsection 1.9(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which
consent shall not be unreasonably withheld), nor shall the Company be liable to any Holder, underwriter or controlling person for any such loss, claim, damage, liability, or action (1) to the
extent that it arises out of or is based upon a Violation that occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by
any such Holder, underwriter or controlling person or (2) in the case of a sale directly by a Holder of Registrable Securities (including a sale of such Registrable Securities through any
underwriter retained by such Holder engaging in a distribution solely on behalf of such Holder), such Violation arises out of a material misstatement or omission contained in a preliminary prospectus
and corrected in a final or amended prospectus, and such Holder failed to deliver a copy of the final or amended prospectus at or prior to the confirmation of 

8

 

the
sale of the Registrable Securities to the person asserting any such loss, claim, damage or liability in any case in which such delivery is required by the Securities Act. 

        (b)    Indemnification by the Holders.    To the extent permitted by law, each Holder joining
in registration will indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company
within the meaning of Section 15 of the Securities Act, any underwriter and any controlling person of any such underwriter, against any losses, claims, damages, or liabilities (joint or
several) to which any of the foregoing persons may become subject, under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages, or liabilities (or
actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written
information (including, without limitation, written negative responses to inquiries) furnished by such Holder expressly for use in connection with such registration; and each such Holder will pay, as
incurred, any legal or other expenses reasonably incurred by any person intended to be indemnified pursuant to this Section 1.9(b), in connection with investigating or defending any such loss,
claim, damage, liability, or action; provided, however, that the indemnity
agreement contained in this Section 1.9(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent
of the Holder, which consent shall not be unreasonably withheld; provided, further, that in no event
shall any indemnity under this Section 1.9(b) exceed the net proceeds from the offering received by such Holder, except in the case of willful fraud by such Holder;  provided, further, that the indemnity under this Section 1.9(b) shall not be deemed to relieve
any underwriter of any of its due diligence obligations. 

        (c)    Procedures.    Promptly after receipt by an indemnified party under this
Section 1.9 of notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying
party under this Section 1.9, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the
extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties;  provided,
however, that an indemnified party (together with all other indemnified parties which may be
represented without conflict by one counsel) shall have the right to retain one separate counsel, with the reasonable fees and expenses to be paid by the indemnifying party, if representation of such
indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented
by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, to the extent prejudicial to its
ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section 1.9, but the omission so to deliver written notice to the
indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 1.9. No indemnifying party, in the defense of any such claim
or litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the
giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. The indemnity agreements contained in this Section 1.9
shall not apply to amounts paid in settlement of any loss, claim, damage, liability or action if such settlement is effected without the consent of the indemnifying party, which consent shall not be
unreasonably withheld. 

9

 

        (d)    Contribution.    If the indemnification provided for in this Section 1.9 is held
by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to therein, then the indemnifying party, in lieu
of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such
proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that
resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable considerations; provided, that in no event shall any
contribution by a Holder under this Section 1.9(d) exceed the net proceeds from the offering received by such Holder, except in the case of willful fraud by such Holder. The relative fault of
the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state
a
material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties' relative intent, knowledge, access to information, and opportunity to correct or
prevent such statement or omission. 

        (e)    Underwriting Agreement.    Notwithstanding the foregoing, to the extent that the
provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions,
the provisions in the underwriting agreement shall control. 

        (f)    Reimbursement.    The contribution required by this Section 1.9 shall be made by
periodic payment during the course of the investigation or defense, as and when bills are submitted to the indemnifying party. 

        (g)    Survival.    The obligations of the Company and Holders under this Section 1.9
shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 1, and otherwise. No indemnifying party, in defense of any such claim or
litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving
by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. 

        1.10    Reports Under Securities Exchange Act of 1934.    With a view to making available to
the Holders the benefits of Rule 144 promulgated under the Securities Act and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to
the public without registration or pursuant to a registration on Form S-3, the Company agrees to: 

        (a)   make
and keep public information available, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the first
registration statement filed by the Company for the offering of its securities to the general public so long as the Company remains subject to the periodic reporting requirements under
Sections 13 or 15(d) of the Exchange Act; 

        (b)   take
such action, including the voluntary registration of its Common Stock under Section 12 of the Exchange Act, as is necessary to enable the Holders to use
Form S-3 for the sale of their Registrable Securities, such action to be taken as soon as practicable after the end of the fiscal year in which the first registration statement
filed by the Company for the offering of its equity securities to the general public is declared effective; 

        (c)   file
with the SEC in a timely manner all reports and other documents as may be required of the Company under the Securities Act and the Exchange Act; and 

10

 

        (d)   furnish
to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the Company that it has complied
with the reporting requirements of SEC Rule 144, the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a
registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company
and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC which
permits the selling of any such securities without registration or pursuant to such form. 

        1.11    Assignment of Registration Rights.    The rights to cause the Company to register
securities granted Holders under Sections 1.2, 1.3 and 1.4 may be assigned to a transferee or assignee in connection with any transfer or assignment of Registrable Securities by a Holder;  provided
that (a) such transfer may otherwise be effected in accordance with applicable securities laws and restrictions on transfer agreed upon
by the Holder and the Company (including those set forth in the Purchase Agreement), (b) notice of such assignment is given to the Company, (c) such transferee or assignee (i) is
a wholly-owned subsidiary or constituent partner, retired partner, member, retired member or shareholder of such Holder, or a beneficiary or grantor of a Holder that is a trust, or (ii) is a
spouse, ancestor or descendant, or (iii) is a trust for the benefit of such Holder or any spouse, ancestor or descendant of such Holder or (iv) acquires from such Holder at least 250,000
shares of Registrable Securities (as appropriately adjusted for stock splits and the like) and (d) such transferee or assignee agrees in writing, within ten (10) days of the transfer, to
be bound by all provisions of this Agreement. Notwithstanding the foregoing, all assignees and transferees of a Holder who acquire less than 250,000 shares of Registrable Securities (as appropriately
adjusted for stock splits and the like) from such Holder shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices or taking any action
under Section 1. 

        1.12    Limitations on Subsequent Registration Rights.    From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Holders of at least a majority of the outstanding Registrable Securities, enter into any agreement with any holder or
prospective holder of any securities of the Company which would allow such holder or prospective holder (a) to include such securities in any registration filed under Section 1.2,1.3 or
1.4 hereof, unless under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of its securities
will not reduce the amount of the Registrable Securities of the Holders which is included or (b) to make a demand registration within 120 days after the effective date of any
registration effected pursuant to Section 1.2. 

        1.13    Market-Standoff Agreement.    

        (a)    Market-Standoff Period; Agreement.    In connection with the
initial public offering of the Company's securities and upon request of the Company or the underwriters managing such offering of the Company's securities, each Holder hereby agrees not to sell, make
any short sale of, loan, grant any option for the purchase of, or otherwise hedge or dispose of any securities of the Company (other than any disposed of in the registration and those acquired by the
Holder in the registration or thereafter in open market transactions) without the prior written consent of the Company or such underwriters, as the case may be, for such period of time (not to exceed
180 days but subject to such extension or extensions of up to 18 days as may be required by the underwriters in order to publish research reports while complying with the
Rule 2711 of the Financial Industry Regulatory Authority, Inc.) from the effective date of such registration as may be requested by the Company or such managing underwriters and to
execute an agreement reflecting the foregoing as may be requested by the underwriters at the time of the Company's initial public offering. 

11

 

 

        (b)    Limitations on Lock-Up.    The obligations
described in Section 1.13(a) shall apply only if all executive officers and directors of the Company, and all one-percent and greater security holders (on a basis assuming full
conversion and exercise of all convertible or exercisable securities) enter into similar agreements. If the Company or the underwriter of any public offering of the Company's securities waives or
terminates any standoff or lockup restrictions imposed on any holder of securities of the Company, then such waiver or termination shall be granted to all Holders subject to standoff or lockup
restrictions pro rata based on the number of shares of Common Stock beneficially held by such holder and the Holders. From and after the date of this
Agreement, the Company shall use its best efforts to ensure that all holders of capital stock of the Company agree to be bound by terms substantially similar to those set forth in this
Section 1.13. 

        (c)    Stop-Transfer Instructions.    In order to enforce
the foregoing covenants, the Company may impose stop-transfer instructions with respect to the securities of each Holder (and the securities of every other person subject to the
restrictions in Section 1.13(a)). 

        (d)    Transferees Bound.    Each Holder agrees that it will not
transfer securities of the Company unless each transferee agrees in writing to be bound by all of the provisions of this Section 1.13. 

        1.14    Termination of Registration Rights.    No Holder shall be entitled to exercise any
registration right provided for in this Section 1 after the earlier of (i) five years following the consummation of a Qualified IPO, or (ii) such time as Rule 144 or
another similar exemption under the Securities Act is available for the sale of all of such Holder's shares during a three-month period without registration, without reference to Rule 144(k). 

        2.    Covenants of the Company.    

        2.1    Delivery of Financial Statements.    Upon written request by a Major Investor, the
Company shall deliver to such Major Investor (other than a Major Investor reasonably deemed by the Board to be a competitor of the Company): 

        (a)   as
soon as practicable, but in any event within 180 days after the end of each fiscal year of the Company, an operations statement for such fiscal year, a balance
sheet of the Company and statement of stockholders' equity as of the end of such year, and a statement of cash flows for such year, such year-end financial reports to be in reasonable
detail, prepared in accordance with generally accepted accounting principles ("GAAP"), and audited and certified by an independent public accounting
firm of nationally recognized standing selected by the Company and accompanied by a report and opinion thereon prepared by such accounting firm; 

        (b)   as
soon as practicable, but in any event within 45 days after the end of each of the first three quarters of each fiscal year of the Company, an unaudited profit
or loss statement, a statement of cash flows for such fiscal quarter and an unaudited balance sheet as of the end of such fiscal quarter; provided, however, that the Strategic Investors shall only be
entitled to receive the financial statements provided for in this Section 2.1(b) for the limited purpose of determining the valuation of such Strategic Investor's investment in the Company; and 

        (c)   as
soon as practicable, but in any event no later than 30 days after the end of each fiscal year, a budget for the next fiscal year, prepared on a quarterly
basis, and approved by the Board and any revised budgets prepared by the Company, provided, however, that the Strategic Investors shall not be entitled to any budgets or information provided for in
this Section 2.1(c). 

12

 

        (d)   Notwithstanding
anything to the contrary contained herein, to the extent that any financial statements or information provided for in Section 2.1(b) contains, in
the Company's reasonable belief, any competitive information, the Company may remove any such competitive information from such financial statements or information before providing them to any
Strategic Investors. 

        2.2    Budget Approval.    The Company's annual operating budget for each fiscal year
following 2008 shall require the approval of any three of the four members of the Board designated by the Rho Nominee, the Aberdare Nominee, the Care Capital Nominee and the Venrock Nominee pursuant
to that certain Amended and Restated Voting Agreement of even date herewith (as each party is defined therein). 

        2.3    Inspection.    The Company shall permit each Major Investor (except a Strategic
Investor or a Major Investor reasonably deemed by the Board to be a competitor of the Company), at such Holder's expense, to visit and inspect the Company's properties, to examine its books of account
and records and to discuss the Company's affairs, finances and accounts with its executive officers, all at such reasonable times as may be requested by the Major Investor;  provided, however, that the Company shall not be obligated pursuant to this Section 2.3 to
provide access to any information which it reasonably considers to be a trade secret. Notwithstanding the above, the Company shall permit any Strategic Investor with reasonable access to the financial
statements of the Company for the limited purpose of determining the valuation of such Strategic Investor's investment in the Company; provided, that to the extent that any financial statements
provided for in this Section 2.3 contains, in the Company's reasonable belief, any competitive information, the Company may remove any such competitive information from such financial
statements before allowing access to any Strategic Investors. 

        2.4    Books and Records.    The Company will maintain true books and records of account in
which full and correct entries will be made of all its business transactions pursuant to a system of accounting established and administered in accordance with generally accepted accounting principles
consistently applied (except as noted therein), and will set aside on its books all such proper accruals and reserves as shall be required under generally accepted accounting principles consistently
applied. 

        2.5    Board Expenses.    The Company will pay for the reasonable travel expenses associated
with the attendance of all board meetings by the members of the Board. 

        2.6    Right of First Offer.    Subject to applicable securities laws and the terms and
conditions specified in this Section 2.6, the Company hereby grants to each Holder a right of first offer with respect to future sales by the Company of its Shares (as hereinafter defined). A
Holder who chooses to exercise the right of first offer may designate as purchasers under such right itself or its partners, members or affiliates in such proportions as it deems appropriate. 

        Each
time the Company proposes to offer any shares of, or securities convertible into or exercisable for any shares of, any class of its capital stock
("Shares"), the Company shall first make an offering of such Shares to each Holder in accordance with the following provisions: 

        (a)   The
Company shall deliver a written notice ("Notice") to the Holders stating (i) its bona
fide intention to offer such Shares, (ii) the number of such Shares to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such
Shares. 

        (b)   Within
15 days after receipt of the Notice, each Holder may elect to purchase or obtain, at the price and on the terms specified in the Notice, up to that portion
of such Shares which equals the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion and exercise of all convertible or exercisable securities then held,
by such Holder bears to the total number of shares of Common Stock then outstanding 

13

 

(assuming
full conversion and exercise of all convertible or exercisable securities); provided, however,
that a Holder's portion may be reduced on a pro rata basis among all Holders if the Board unanimously determines that such a reduction is necessary to
provide a sufficient incentive for a new investor to purchase shares, which investor may be an existing Holder. The Company shall promptly, in writing, inform each Holder that purchases all the shares
available to it (each, a "Fully-Exercising Investor") of any other Holder's failure to do likewise. During the ten-day period commencing
after receipt of such information, each Fully-Exercising Investor shall be entitled to obtain all or any part of the Shares for which Holders were entitled to subscribe but which were not subscribed
for by the Holders; provided, that if the Fully-Exercising Investors elect to purchase in the aggregate more than 100% of the aggregate number of such
Shares, the number of such Shares sold to each Fully-Exercising Investor shall be reduced proportionately in accordance with each electing Fully-Exercising Investor's respective pro-rata
shares, which for this purpose shall mean the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion and exercise of all convertible or exercisable
securities then held, by such Fully-Exercising Investor bears to the total number of shares of Common Stock issued and held, or issuable upon conversion and exercise of all convertible or exercisable
securities then held by all Fully-Exercising Investors electing to purchase such available Shares (in such cases, assuming full conversion and exercise of all convertible or exercisable securities). 

        (c)   The
Company may, during the 45-day period following the expiration of the 10-day period provided in subsection 2.6(b) hereof, offer the
remaining un-subscribed portion of the Shares to any person or persons at a price not less than, and upon terms no more favorable to the offeree than those specified in the Notice. If the
Company does not enter into an agreement for the sale of the Shares within such period, or if such agreement is not consummated within 60 days of the execution thereof, the right provided
hereunder shall be deemed to be revived and such Shares shall not be offered unless first re-offered to the Holders in accordance herewith. 

        (d)   The
term "Shares" shall not include (i) securities offered to the public generally pursuant to a registration
statement under the Securities Act, (ii) Common Stock reserved for issuance pursuant to the Company's 2001 Equity Incentive Plan, as amended, and additional shares of Common Stock (or options
therefor) issued or issuable to employees, consultants and directors, pursuant to other plans or agreements approved by the Board for the primary purpose of soliciting or retaining their services,
(iii) securities issued or issuable pursuant to the conversion or exercise of convertible or exercisable securities that are outstanding as of the date hereof or that are issued in compliance
with this Section, (iv) securities issued or issuable in connection with a bona fide business acquisition of or by the Company, whether by
merger, consolidation, sale of assets, sale or exchange of stock or otherwise, approved by the Board, (v) securities issued or issuable to financial institutions, landlords, lessors or other
similar institutions in connection with commercial credit arrangements, real estate transactions, equipment financings or similar transactions, the primary purpose of which it other than to obtain
equity financing for the Company through the issuance of equity securities, approved by the Board, (vi) the Series E Preferred Stock issued or issuable pursuant to the Purchase Agreement
(vii) securities issued or issuable pursuant to a stock split, stock dividend, combination or like event or (viii) securities issued or issuable pursuant to a strategic alliance or
partnering arrangement entered into primarily for non-capital raising purposes and approved by the Board. In addition to the foregoing, the right of first offer in this Section 2.6
shall not be applicable with respect to any Holder and any subsequent securities issuance, if (i) at the time of such subsequent securities issuance, the Holder is not an "accredited investor,"
as that term is then defined in Rule 501(a) under the Securities Act, and (ii) such subsequent securities issuance is otherwise being offered only to accredited investors. 

14

 

        2.7    Employee Agreements.    The Company shall cause all of its current and future employees
and consultants to execute confidential information and invention assignment agreements or similar agreements providing for the assignment of inventions to the Company. Except as specifically approved
by the Board, all shares of Common Stock issued, and all options granted, after the date of this Agreement by the Company to its employees, consultants, officers and non-investor directors
for shares of Common Stock shall (i) be subject to a right of first refusal in favor of the Company, and (ii) be subject to standard transfer restrictions. The rights of the Company
pursuant to (i) above shall be assignable by the Company. 

        2.8    Termination of Covenants.    

        (a)   The
covenants set forth in Sections 2.1 through Section 2.6 shall terminate as to each Holder and be of no further force or effect (i) immediately
prior to the consummation of a Qualified IPO, or (ii) upon the closing of (A) any consolidation or merger of the Company with or into any other corporation or entity, (B) a sale
of substantially all of the assets or stock of the Company or (C) any other transaction or series of transactions (other than equity financing transactions),  provided that, in each of cases (A),
(B) and (C), as a result of such consolidation, merger, sale or other transaction, the stockholders of the
Company immediately prior to the closing thereof, and as a result of the consideration issued therein, do not own immediately after such closing, in approximately the same relative percentages, at
least 50% of the voting power of the Company, the surviving entity or its parent. 

        (b)   The
covenants set forth in Sections 2.1 through 2.4 shall terminate as to each Holder and be of no further force or effect when the Company first becomes subject
to the periodic reporting requirements of Sections 13 or 15(d) of the Exchange Act, if this occurs earlier than the events described in Section 2.7(a) above. 

        3.    Miscellaneous.    

        3.1    Entire Agreement.    This Agreement constitutes the entire agreement among the parties
hereto pertaining to the subject matter hereof, and any and all other written or oral agreements relating to the subject matter hereof existing among any of the parties hereto are expressly canceled. 

        3.2    Recapitalizations, Etc.    The provisions of this Agreement (including any calculation
of share ownership) shall apply, to the full extent set forth herein with respect to the Registrable Securities and to the Common Stock, to any and all shares of capital stock of the Company or any
capital stock, partnership or member units or any other security evidencing ownership interests in any successor or assign of the Company (whether by merger, consolidation, sale of assets or
otherwise) which may be issued in respect of, in exchange for, or in substitution of the Common Stock by reason of any stock dividend, split, combination, recapitalization, liquidation,
reclassification, merger, consolidation or otherwise. 

        3.3    Successors and Assigns.    Except as otherwise provided in this Agreement, and subject
to the restriction on transfer set forth in the Purchase Agreement, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and
assigns of the parties (including transferees of any of the Preferred Stock or any Common Stock issued upon conversion thereof). Nothing in this Agreement, express or implied, is intended to confer
upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly
provided in this Agreement. 

        3.4    Amendments and Waivers.    This Agreement may be amended or waived only with the
written consent of the Company and the holders of at least 70% of the Registrable Securities then outstanding. The Investors and their successors and assigns acknowledge that by operation of this 

15

 

Section 3.4,
the holders of at least 70% of the then outstanding Registrable Securities, when acting together with the Company, will have the right and power to diminish or eliminate any rights
or increase any or all obligations under this Agreement. 

        3.5    Notices.    Unless otherwise provided, any notice required or permitted by this
Agreement shall be in writing and shall be deemed sufficient upon delivery, when delivered personally or by nationally recognized overnight courier or sent by electronic mail, or if mailed to a
domestic address, on the third business day after being deposited in the U.S. mail, as certified or registered mail, return receipt requested, with postage prepaid, and addressed to the party to be
notified at such party's address or electronic mail address as set forth below or on Exhibit A hereto or as subsequently modified by written notice and if to the Company, (a) addressed
to Anacor Pharmaceuticals, Inc., 1020 East Meadow Circle, Palo Alto, CA 94303-4230, Attn: David Perry, E-mail: dperry@anacor.com, (b) with a copy to Mark B.
Weeks, Cooley Godward Kronish LLP, Five Palo Alto
Square, 3000 El Camino Real, Palo Alto, CA 94306-2155, E-mail: mweeks@cooley.com. 

        3.6    Severability.    If one or more provisions of this Agreement are held to be
unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such
provision, then (a) such provision shall be excluded from this Agreement, (b) the balance of the Agreement shall be interpreted as if such provision were so excluded and (c) the
balance of the Agreement shall be enforceable in accordance with its terms. 

        3.7    Delays or Omissions; Remedies Cumulative.    No delay or omission to exercise any
right, power or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such
non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or
default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or
approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must
be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be
cumulative and not alternative. 

        3.8    Attorneys' Fees.    If any action at law or in equity (including arbitration) is
necessary to enforce or interpret the terms of any this Agreement, the prevailing party shall be entitled to reasonable attorneys' fees, costs and necessary disbursements in addition to any other
relief to which such party may be entitled. 

        3.9    Governing Law.    This Agreement and all acts and transactions pursuant hereto shall be
governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of laws. 

        3.10    Counterparts.    This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

        3.11    Titles and Subtitles.    The titles and subtitles used in this Agreement are used for
convenience only and are not to be considered in construing or interpreting this Agreement. 

        3.12    Aggregation of Stock.    All shares of Company stock held or acquired by affiliated
Persons (including former and current partners, former and current members and former and 

16

 

current
stockholders) shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

        3.13    Confidentiality.    Each Holder agrees that, except with the prior written permission
of the applicable party, it shall at all times keep confidential and not divulge, furnish or make accessible to anyone any confidential information, knowledge or data concerning or relating to the
business or financial affairs of the Company or any other party to which such Holder has been or shall become privy by reason of this Agreement (including Sections 2.1 and 2.3 hereof). The
provisions of this Section 3.13 shall be in addition to, and not in substitution for, the provisions of any separate nondisclosure agreement executed by the parties hereto with respect to the
transactions contemplated hereby. 

        3.14    Additional Parties.    Persons who become "Purchasers" of the Company's
Series E Preferred Stock after the effective date of this Agreement pursuant to and in accordance with the Purchase Agreement and who execute signature pages to this Agreement shall become
parties hereto, and no consent or waiver of any other party hereto, other than the Company, shall be required to add any such additional party. 

        3.15    Strategic Investors Other Rights.    Nothing herein shall effect any rights that a
Strategic Investor has pursuant to, as applicable, (a) that certain License, Development, and Commercialization Agreement between Schering Corporation and the Company dated as of
February 2, 2007, as amended, or (b) that certain Research and Development Collaboration Option and License Agreement between the Company and SmithKline Beecham Corporation d/b/a
GlaxoSmithKline, effective as of October 5, 2007. 

[Signature
Pages Follow] 

17

 
        The parties hereto have executed this Amended and Restated Investors' Rights Agreement as of the date first above written. 

					
	 	 	 COMPANY:
	

 	
 	
 ANACOR PHARMACEUTICALS, INC.
	

 	
 	
By:	
 	
/s/ DAVID PERRY

 
	 	 	Name:	 	David Perry
	 	 	Title:	 	Chief Executive Officer
	

 	
 	
Address:	
 	
1020 East Meadow Circle

Palo Alto, California 94303

SIGNATURE PAGE TO THE AMENDED AND

RESTATED INVESTORS' RIGHTS AGREEMENT  

					
	 	 	 STRATEGIC INVESTOR:
	

 	
 	
 SMITHKLINE BEECHAM

    CORPORATION D/B/A GLAXOSMITHKLINE
	

 	
 	
By:	
 	
/s/ WILLIAM J. MOSHER

 
	 	 	Name:	 	William J. Mosher

 
	 	 	Title:	 	Secretary

 
	

 	
 	
Address:	
 	
200 N. 17th Street

Philadelphia, PA 19102

SIGNATURE PAGE TO THE AMENDED AND

RESTATED INVESTORS' RIGHTS AGREEMENT  

					
	 	 	 STRATEGIC INVESTOR:
	

 	
 	
 SCHERING CORPORATION
	

 	
 	
By:	
 	
/s/ DAVID PIACQUAD

 
	 	 	Name:	 	David Piacquad

 
	 	 	Title:	 	Vice President

 
	

 	
 	
Address:	
 	
2000 Galloping Hill Road

Kenilworth, NJ 07033

SIGNATURE PAGE TO THE AMENDED AND

RESTATED INVESTORS' RIGHTS AGREEMENT  

					
	 	 	 INVESTORS:
	

 	
 	
 RHO VENTURES IV, L.P.
	

 	
 	
By:	
 	
Rho Management Ventures IV, L.L.C.,

General Partner
	

 	
 	
By:	
 	
/s/ MARK LESCHLY

 
	 	 	Name:	 	Mark Leschly

 
	 	 	Title:	 	Managing Member

 
	

 	
 	
Address:	
 	
152 W. 57th Street, 23rd Floor

New York, New York 10019
	

 	
 	
 RHO VENTURES IV GmbH & CO.

BETEILIGUNGS KG
	

 	
 	
By:	
 	
Rho Capital Partners Verwaltungs GmbH,

General Partner
	

 	
 	
By:	
 	
/s/ MARK LESCHLY

 
	 	 	Name:	 	Mark Leschly

 
	 	 	Title:	 	Managing Director

 
	

 	
 	
Address:	
 	
152 W. 57th Street, 23rd Floor

New York, New York 10019

SIGNATURE PAGE TO THE AMENDED AND

RESTATED INVESTORS' RIGHTS AGREEMENT  

					
	 	 	 INVESTORS:
	

 	
 	
 RHO VENTURES IV (QP), L.P.
	

 	
 	
By:	
 	
Rho Management Ventures IV, L.L.C.,

General Partner
	

 	
 	
By:	
 	
/s/ MARK LESCHLY

 
	 	 	Name:	 	Mark Leschly

 
	 	 	Title:	 	Managing Member

 
	

 	
 	
Address:	
 	
152 W. 57th Street, 23rd Floor

New York, New York 10019
	

 	
 	
 RHO MANAGEMENT TRUST I
	

 	
 	
By:	
 	
Rho Capital Partners, Inc., as

Investment Adviser
	

 	
 	
By:	
 	
/s/ MARK LESCHLY

 
	 	 	Name:	 	Mark Leschly

 
	 	 	Title:	 	Managing Partner

 
	

 	
 	
Address:	
 	
152 W. 57th Street, 23rd Floor

New York, New York 10019

SIGNATURE PAGE TO THE AMENDED AND

RESTATED INVESTORS' RIGHTS AGREEMENT  

 

					
	 	 	 INVESTORS:
	

 	
 	
 ABERDARE VENTURES II, L.P.
	

 	
 	
By:	
 	
Aberdare GP II, LLC, its General Partner
	

 	
 	
By:	
 	
/s/ PAUL H. KLINGENSTEIN

 
	 	 	Name:	 	Paul H. Klingenstein

 
	 	 	Title:	 	Member

 
	

 	
 	
Address:	
 	
One Embarcadero Center, #4000
	 	 	 	 	San Francisco, California 94111
	

 	
 	
 ABERDARE VENTURES II (BERMUDA), L.P.
	

 	
 	
By:	
 	
Aberdare GP II, LLC, its General Partner
	

 	
 	
By:	
 	
/s/ JOHN H. ODDEN

 
	 	 	Name:	 	John H. Odden

 
	 	 	Title:	 	Member

 
	

 	
 	
Address:	
 	
One Embarcadero Center, #4000
	 	 	 	 	San Francisco, California 94111

SIGNATURE PAGE TO THE AMENDED AND

RESTATED INVESTORS' RIGHTS AGREEMENT  

					
	 	 	 INVESTORS:
	

 	
 	
 ABERDARE II ANNEX FUND, L.P.
	

 	
 	
By:	
 	
Aberdare GP II, LLC its General Partner
	

 	
 	
By:	
 	
/s/ JOHN H. ODDEN

 
	 	 	Name:	 	John H. Odden

 
	 	 	Title:	 	Manager

 
	

 	
 	
Address:	
 	
One Embarcadero Center, #4000
	 	 	 	 	San Francisco, California 94111
	

 	
 	
/s/ PAUL H. KLINGENSTEIN

 
	 	 	 PAUL H. KLINGENSTEIN
	

 	
 	
/s/ JOHN H. ODDEN

 
	 	 	 JOHN H. ODDEN

SIGNATURE PAGE TO THE AMENDED AND

RESTATED INVESTORS' RIGHTS AGREEMENT  

					
	 	 	 INVESTORS:
	

 	
 	
 CARE CAPITAL INVESTMENTS II, LP
	

 	
 	
By:	
 	
Care Capital II, LLC

as general partner of Care Capital Investments II, LP
	

 	
 	
By:	
 	
/s/ RICHARD J. MARKHAM

 
	 	 	Name:

(print)	 	Richard J. Markham

 
	 	 	Title:	 	Partner

 
	

 	
 	
Address:	
 	
47 Hulfish Street, Suite 310
	 	 	 	 	Princeton, NJ 08542
	

 	
 	
 CARE CAPITAL OFFSHORE INVESTMENTS II, LP
	

 	
 	
By:	
 	
Care Capital II, LLC

as general partner of Care Capital Offshore Investments II, LP
	

 	
 	
By:	
 	
/s/ RICHARD J. MARKHAM

 
	 	 	Name:

(print)	 	Richard J. Markham

 
	 	 	Title:	 	Partner

 
	

 	
 	
Address:	
 	
47 Hulfish Street, Suite 310
	 	 	 	 	Princeton, NJ 08542

SIGNATURE PAGE TO THE AMENDED AND

RESTATED INVESTORS' RIGHTS AGREEMENT  

					
	 	 	 INVESTORS:
	

 	
 	
 VENROCK PARTNERS, L.P.

by its General Partner, Venrock Partners Management, LLC
	

 	
 	
By:	
 	
/s/ ANDERS D. HOVE

 
	 	 	Name:	 	Anders D. Hove

 
	 	 	Title:	 	Member

 
	

 	
 	
Address:	
 	
530 Fifth Avenue, 22nd floor

New York, NY 10036
	

 	
 	
 VENROCK ASSOCIATES IV, L.P.

by its General Partner, Venrock Management IV, LLC
	

 	
 	
By:	
 	
/s/ ANDERS D. HOVE

 
	 	 	Name:	 	Anders D. Hove

 
	 	 	Title:	 	Member

 
	

 	
 	
Address:	
 	
530 Fifth Avenue, 22nd floor

New York, NY 10036
	

 	
 	
 VENROCK ENTREPRENEURS FUND IV, L.P.

by its General Partner, VEF Management IV, LLC
	

 	
 	
By:	
 	
/s/ ANDERS D. HOVE

 
	 	 	Name:	 	Anders D. Hove

 
	 	 	Title:	 	Member

 
	

 	
 	
Address:	
 	
530 Fifth Avenue, 22nd floor

New York, NY 10036

SIGNATURE PAGE TO THE AMENDED AND

RESTATED INVESTORS' RIGHTS AGREEMENT  

					
	 	 	 INVESTORS:
	

 	
 	
 RED ABBEY VENTURE PARTNERS (QP), LP
	

 	
 	
By: Red Abbey Ventures Partners, LLC, its General Partner
	

 	
 	
By:	
 	
/s/ MATT ZUGA

  Matt Zuga, its Managing Member
	

 	
 	
Address:	
 	
2330 West Joppa Road

Suite 330

Baltimore, MD 21093
	

 	
 	
 RED ABBEY VENTURE PARTNERS, LP
	

 	
 	
By: Red Abbey Ventures Partners, LLC, its General Partner
	

 	
 	
By:	
 	
/s/ MATT ZUGA

  Matt Zuga, its Managing Member
	

 	
 	
Address:	
 	
2330 West Joppa Road

Suite 330

Baltimore, MD 21093
	

 	
 	
 RED ABBEY CEO'S FUND, LP
	

 	
 	
By: Red Abbey Ventures Partners, LLC, its General Partner
	

 	
 	
By:	
 	
/s/ MATT ZUGA

  Matt Zuga, its Managing Member
	

 	
 	
Address:	
 	
2330 West Joppa Road

Suite 330

Baltimore, MD 21093

SIGNATURE PAGE TO THE AMENDED AND

RESTATED INVESTORS' RIGHTS AGREEMENT  

 

					
	 	 	 INVESTORS:
	

 	
 	
 MCADAMS-SHAPIRO FAMILY TRUST

DATED MAY 24, 1999
	

 	
 	
By:	
 	
/s/ LUCY SHAPIRO

 
	 	 	Name:	 	Lucy Shapiro

 
	 	 	Title:	 	Trustee

 
	

 	
 	
Address:	
 	
724 Esplanada Way

Stanford, CA 94305

SIGNATURE PAGE TO THE AMENDED AND

RESTATED INVESTORS' RIGHTS AGREEMENT  

					
	 	 	 INVESTORS:
	

 	
 	
/s/ STEPHEN BENKOVIC

 STEPHEN BENKOVIC
	

 	
 	
Address:	
 	
771 Teaberry Lane

State College, PA 16803

SIGNATURE PAGE TO THE AMENDED AND

RESTATED INVESTORS' RIGHTS AGREEMENT  

					
	 	 	 INVESTORS:
	

 	
 	
 GC&H INVESTMENTS, LLC
	

 	
 	
By:	
 	
/s/ JOHN L. CARDOZA

 
	 	 	Name:	 	John L. Cardoza

 
	 	 	Title:	 	Managing Member

 
	

 	
 	
 GC&H INVESTMENTS
	

 	
 	
By:	
 	
/s/ JOHN L. CARDOZA

 
	 	 	Name:	 	John L. Cardoza

 
	 	 	Title:	 	Managing Member

 

SIGNATURE PAGE TO THE AMENDED AND

RESTATED INVESTORS' RIGHTS AGREEMENT  

  EXHIBIT A  

 LIST OF INVESTORS  

Rho
Ventures IV, L.P.

152 West 57th, 23rd Floor

New York, NY 10019

fax (212) 751-3613 

Rho
Ventures IV GmbH & Co. Beteiligungs KG

152 West 57th, 23rd Floor

New York, NY 10019

fax (212) 751-3613 

Rho
Ventures IV (QP), L.P.

152 West 57th, 23rd Floor

New York, NY 10019

fax (212) 751-3613 

Rho
Management Trust I

152 West 57th, 23rd Floor

New York, NY 10019

fax (212) 751-3613 

Aberdare
Ventures II, L.P.

One Embarcadero Center

San Francisco, CA 94111

fax (415) 392-4264 

Aberdare
Ventures II (Bermuda), L.P.

c/o Aberdare Ventures II, L.P.

One Embarcadero Center

San Francisco, CA 94111

fax (415) 392-4264 

Paul
H. Klingenstein

c/o Aberdare Ventures II, L.P.

One Embarcadero Center

San Francisco, CA 94111

fax (415) 392-4264 

John
H. Odden

c/o Aberdare Ventures II, L.P.

One Embarcadero Center

San Francisco, CA 94111

fax (415) 392-4264 

Care
Capital Investments II, LP

47 Hulfish Street, Suite 310

Princeton, NJ 08542

fax (609) 683-5787 

Care
Capital Offshore Investments II, LP

47 Hulfish Street, Suite 310

Princeton, NJ 08542

fax (609) 683-5787 

Venrock
Partners, L.P.

530 Fifth Avenue, 22nd floor

New York, NY 10036 

Venrock
Associates IV, L.P.

530 Fifth Avenue, 22nd floor

New York, NY 10036 

Venrock
Entrepreneurs Fund IV, L.P.

530 Fifth Avenue, 22nd floor

New York, NY 10036 

Red
Abbey Venture Partners (QP), LP

2330 West Joppa Road

Suite 330

Lutherville, MD 21093 

Red
Abbey Venture Partners, LP

2330 West Joppa Road

Suite 330

Lutherville, MD 21093 

Red
Abbey CEO's Fund, LP

2330 West Joppa Road

Suite 330

Lutherville, MD 21093 

Stephen
Benkovic 

McAdams-Shapiro
Family Trust dated May 24, 1999 

HEWM/VLG
Investments LLC

        Five Palo Alto Square

        3000 El Camino Real

Palo Alto, CA 94306-2155 

VLG
Investments 2006 LLC

        Five Palo Alto Square

        3000 El Camino Real

Palo Alto, CA 94306-2155 

Mark
B. Weeks

Five Palo Alto Square

3000 El Camino Real

Palo Alto, CA 94306-2155 

Lighthouse
Capital Partners V, L.P.

500 Drakes Landing Rd.

Greenbrae, CA 94904

Attn: Contracts Administration 

SmithKline
Beecham Corporation d/b/a GlaxoSmithKline

One Franklin Plaza

Philadelphia, PA 19101 

Schering
Corporation

2000 Galloping Hill Road

Kenilworth, NJ 07033-0530

GC&H
Investments, LLC

        c/o Cooley Godward Kronish LLP

        Five
Palo Alto Square

        3000 El Camino Real

Palo Alto, CA 94306-2155 

GC&H
Investments

        c/o Cooley Godward Kronish LLP

        Five Palo Alto Square

        3000 El Camino Real

Palo Alto, CA 94306-2155 

 

 ANACOR PHARMACEUTICALS, INC.

AMENDMENT NO. 1 TO AMENDED AND RESTATED

INVESTORS' RIGHTS AGREEMENT  

        This Amendment No. 1 (the "Amendment") to Amended and Restated Investors' Rights
Agreement dated as of December 24, 2008 by and among Anacor Pharmaceuticals, Inc., a Delaware corporation (the "Company"), the investors
listed on Exhibit A thereto, The Pennsylvania State University and Stanford University (the "Rights Agreement"), is made as of July 22,
2010, by and among the Company and the holders of at least 70% of the outstanding Registrable Securities (as defined in the Rights Agreement) (the "Requisite
Holders"). 

RECITALS  

        A.    The
Company and Lighthouse Capital Partners V, L.P. (the "Lender") have entered into that certain Amendment
No. 3 to Loan and Security Agreement dated as of January 28, 2010 (the "Loan Amendment") pursuant to which Lender restructured the terms
of its loan to the Company. Furthermore, pursuant to the terms of the Loan Amendment, the Company issued to the Lender a warrant (the "Loan Amendment
Warrant") to purchase shares of the Company's Series E Preferred Stock (the "Series E Preferred"). 

        B.    The
parties desire to amend the Rights Agreement to grant to Lender certain registration rights with respect to the shares of Common Stock issued or issuable upon
conversion of the Series E Preferred issued or issuable upon exercise of the Loan Amendment Warrant. 

        C.    Pursuant
to Section 1.12 of the Rights Agreement, the Company shall not, without the prior written consent of the Holders (as defined therein) of a majority of the
outstanding Registrable Securities, enter into any agreement with any holder or prospective holder of any securities of the Company which would grant such holder certain registration rights. 

        D.    Pursuant
to Section 3.4 of the Rights Agreement, the Rights Agreement may be amended only with the written consent of the Company and the holders of at least 70%
of the Registrable Securities then outstanding. 

        E.    The
parties hereto desire to enter into this Amendment in accordance with Sections 1.12 and 3.4 of the Rights Agreement. 

AGREEMENT  

        NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein, the Company and the Requisite Holders hereby
agree that the Rights Agreement shall be amended, and further agree as follows: 

        1.    Definition of Registrable Securities.    Section 1.1(l)
is hereby amended and restated in its entirety as follows: 

        "(l)
The term "Registrable Securities" means (i) the shares of Common Stock issuable or issued upon conversion of the Preferred
Stock held by the Investors, provided that shares of Common Stock issued or issuable upon conversion of Series D Preferred Stock or upon
conversion of Series E Preferred Stock issued upon exercise of warrants held by Lighthouse Capital Partners V, LP or its affiliates shall not be Registrable Securities for the purposes
of Section 2 hereunder, and (ii) any other shares of Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security which is
issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares listed in clause (i) and this clause (ii);  provided, however, that the
foregoing definition shall exclude in all 

1

 

cases
any Registrable Securities sold by a Holder in a transaction in which its rights under this Agreement are not assigned. Notwithstanding the foregoing, securities shall only be treated as
Registrable Securities if and so long as they have not been (A) sold to or through a broker or dealer or underwriter in a public distribution or a public securities transaction, or
(B) sold in a transaction exempt from the registration and prospectus delivery requirements of the Securities Act under Section 4(1) thereof so that all transfer restrictions, and
restrictive legends with respect thereto, if any, are removed upon the consummation of such sale." 

        2.    Governing Law.    This Amendment and all acts and transactions
pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to
principles of conflicts of law. 

        3.    Counterparts.    This Amendment may be executed in two or more
counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. 

        4.    Titles and Subtitles.    The titles and subtitles used in this
Amendment are used for convenience only and are not to be considered in construing or interpreting this Amendment. 

        5.    Entire Agreement.    The Rights Agreement and this Amendment
constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof. Except as specifically provided in this Amendment, the Rights Agreement
shall remain in full force and effect. 

        6.    Definitions.    Capitalized terms not otherwise defined herein
shall have the meaning set forth in the Rights Agreement. 

[Signature
Pages Follow] 

2

        The
parties hereto have executed this Amendment No. 1 to Amended and Restated Investors' Rights Agreement as of the date first written above. 

 

 

					
	 
	 	 
	 	 

	 	 	 COMPANY:
	

 	
 	
 ANACOR PHARMACEUTICALS, INC.
	

 	
 	
By:	
 	
/s/ DAVID PERRY

 
	 	 	Name:	 	David Perry

 
	 	 	Title:	 	Chief Executive Officer

 
	

 	
 	
Address:	
 	
1020 East Meadow Circle

Palo Alto, California 94303

 

 SIGNATURE PAGE TO AMENDMENT NO. 1 TO

AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

ANACOR PHARMACEUTICALS, INC.

        The
parties hereto have executed this Amendment No. 1 to Amended and Restated Investors' Rights Agreement as of the date first written above. 

 

 

					
	 
	 	 
	 	 

	 	 	 REQUISITE HOLDERS:
	

 	
 	
 RHO VENTURES IV, L.P.
	

 	
 	
By:	
 	
Rho Management Ventures IV, L.L.C., General Partner
	

 	
 	
By:	
 	
/s/ JEFF I. MARTIN

 
	 	 	Name:	 	Jeff I. Martin

 
	 	 	Title:	 	Attorney-in-Fact

 
	

 	
 	
Address:	
 	
152 W. 57th Street, 23rd Floor

New York, New York 10019
	

 	
 	
 RHO VENTURES IV GmbH & CO. BETEILIGUNGS KG
	

 	
 	
By:	
 	
Rho Capital Partners Verwaltungs GmbH, General Partner
	

 	
 	
By:	
 	
/s/ JEFF I. MARTIN

 
	 	 	Name:	 	Jeff I. Martin

 
	 	 	Title:	 	Attorney-in-Fact

 
	

 	
 	
Address:	
 	
152 W. 57th Street, 23rd Floor

New York, New York 10019

 

 SIGNATURE PAGE TO AMENDMENT NO. 1 TO

AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

ANACOR PHARMACEUTICALS, INC.

        The
parties hereto have executed this Amendment No. 1 to Amended and Restated Investors' Rights Agreement as of the date first written above. 

 

 

					
	 
	 	 
	 	 

	 	 	 REQUISITE HOLDERS:
	

 	
 	
RHO VENTURES IV (QP), L.P.
	

 	
 	
By:	
 	
Rho Management Ventures IV, L.L.C., General Partner
	

 	
 	
By:	
 	
/s/ JEFF I. MARTIN

 
	 	 	Name:	 	Jeff I. Martin

 
	 	 	Title:	 	Attorney-in-Fact

 
	

 	
 	
Address:	
 	
152 W. 57th Street, 23rd Floor

New York, New York 10019
	

 	
 	
 RHO MANAGEMENT TRUST I
	

 	
 	
By:	
 	
Rho Capital Partners, Inc., as Investment Adviser
	

 	
 	
By:	
 	
/s/ JEFF I. MARTIN

 
	 	 	Name:	 	Jeff I. Martin

 
	 	 	Title:	 	Attorney-in-Fact

 
	

 	
 	
Address:	
 	
152 W. 57th Street, 23rd Floor

New York, New York 10019

 

 SIGNATURE PAGE TO AMENDMENT NO. 1 TO

AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

ANACOR PHARMACEUTICALS, INC.

        The
parties hereto have executed this Amendment No. 1 to Amended and Restated Investors' Rights Agreement as of the date first written above. 

 

 

					
	 
	 	 
	 	 

	 	 	 REQUISITE HOLDERS:
	

 	
 	
ABERDARE VENTURES II, L.P.
	

 	
 	
By:	
 	
Aberdare GP II, LLC, its General Partner
	

 	
 	
By:	
 	
/s/ JOHN H. ODDEN

 
	 	 	Name:	 	John H. Odden

 
	 	 	Title:	 	Member

 
	

 	
 	
Address:	
 	
One Embarcadero Center, #4000

San Francisco, California 94111
	

 	
 	
 ABERDARE VENTURES II (BERMUDA), L.P.
	

 	
 	
By:	
 	
Aberdare GP II, LLC its General Partner
	

 	
 	
By:	
 	
/s/ JOHN H. ODDEN

 
	 	 	Name:	 	John H. Odden

 
	 	 	Title:	 	Member

 
	

 	
 	
Address:	
 	
One Embarcadero Center, #4000

San Francisco, California 94111
	

 	
 	
 ABERDARE II ANNEX FUND, L.P.
	

 	
 	
By:	
 	
Aberdare GP II, LLC its General Partner
	

 	
 	
By:	
 	
/s/ JOHN H. ODDEN

 
	 	 	Name:	 	John H. Odden

 
	 	 	Title:	 	Member

 
	

 	
 	
Address:	
 	
One Embarcadero Center, #4000

San Francisco, California 94111

 

 SIGNATURE PAGE TO AMENDMENT NO. 1 TO

AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

ANACOR PHARMACEUTICALS, INC.

        The
parties hereto have executed this Amendment No. 1 to Amended and Restated Investors' Rights Agreement as of the date first written above. 

 

 

					
	 
	 	 
	 	 

	 	 	 REQUISITE HOLDERS:
	

 	
 	
/s/ PAUL H. KLINGENSTEIN

  Paul H. Klingenstein
	

 	
 	
/s/ JOHN H. ODDEN

  John H. Odden

 

 SIGNATURE PAGE TO AMENDMENT NO. 1 TO

AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

ANACOR PHARMACEUTICALS, INC.

        The
parties hereto have executed this Amendment No. 1 to Amended and Restated Investors' Rights Agreement as of the date first written above. 

 

 

					
	 
	 	 
	 	 

	 	 	 REQUISITE HOLDERS:
	

 	
 	
CARE CAPITAL INVESTMENTS II, LP
	

 	
 	
By:	
 	
Care Capital II, LLC

as general partner of Care

Capital Investments II, LP
	

 	
 	
By:	
 	
/s/ RICHARD J. MARKHAM

 
	 	 	Name:	 	Richard J. Markham

 
	 	 	Title:	 	Partner

 
	

 	
 	
Address:	
 	
47 Hulfish Street, Suite 310

Princeton, NJ 08542
	

 	
 	
 CARE CAPITAL OFFSHORE

INVESTMENTS II, LP
	

 	
 	
By:	
 	
Care Capital II, LLC

as general partner of Care

Capital Offshore Investments II, LP
	

 	
 	
By:	
 	
/s/ RICHARD J. MARKHAM

 
	 	 	Name:	 	Richard J. Markham

 
	 	 	Title:	 	Partner

 
	

 	
 	
Address:	
 	
47 Hulfish Street, Suite 310

Princeton, NJ 08542

 

 SIGNATURE PAGE TO AMENDMENT NO. 1 TO

AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

ANACOR PHARMACEUTICALS, INC.

        The
parties hereto have executed this Amendment No. 1 to Amended and Restated Investors' Rights Agreement as of the date first written above. 

 

 

					
	 
	 	 
	 	 

	 	 	 REQUISITE HOLDERS:
	

 	
 	
VENROCK PARTNERS, L.P.

by its General Partner, Venrock

Partners Management, LLC
	

 	
 	
By:	
 	
/s/ ANDERS D. HOVE

 
	 	 	Name:	 	Anders D. Hove

 
	 	 	Title:	 	Member

 
	

 	
 	
Address:	
 	
530 Fifth Avenue, 22nd floor

New York, NY 10036
	

 	
 	
 VENROCK ASSOCIATES IV, L.P.

by its General Partner, Venrock

Management IV, LLC
	

 	
 	
By:	
 	
/s/ ANDERS D. HOVE

 
	 	 	Name:	 	Anders D. Hove

 
	 	 	Title:	 	Member

 
	

 	
 	
Address:	
 	
530 Fifth Avenue, 22nd floor

New York, NY 10036
	

 	
 	
 VENROCK ENTREPRENEURS FUND IV, L.P.

by its General Partner, VEF

Management IV, LLC
	

 	
 	
By:	
 	
/s/ ANDERS D. HOVE

 
	 	 	Name:	 	Anders D. Hove

 
	 	 	Title:	 	Member

 
	

 	
 	
Address:	
 	
530 Fifth Avenue, 22nd floor

New York, NY 10036

 

 SIGNATURE PAGE TO AMENDMENT NO. 1 TO

AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

ANACOR PHARMACEUTICALS, INC.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}]]